<?xml version='1.0' encoding='utf-8'?>
<document id="19500405"><sentence text="Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines."><entity charOffset="0-10" id="DDI-PubMed.19500405.s1.e0" text="Paclitaxel" /><entity charOffset="58-71" id="DDI-PubMed.19500405.s1.e1" text="deoxycytidine" /><entity charOffset="83-91" id="DDI-PubMed.19500405.s1.e2" text="cytidine" /><pair ddi="false" e1="DDI-PubMed.19500405.s1.e0" e2="DDI-PubMed.19500405.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19500405.s1.e0" e2="DDI-PubMed.19500405.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19500405.s1.e0" e2="DDI-PubMed.19500405.s1.e2" /><pair ddi="false" e1="DDI-PubMed.19500405.s1.e1" e2="DDI-PubMed.19500405.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19500405.s1.e1" e2="DDI-PubMed.19500405.s1.e2" /></sentence><sentence text="We observed that paclitaxel altered the pharmacokinetic properties of gemcitabine in patients with non-small cell lung cancer (NSCLC) and limited the accumulation of gemcitabine and its metabolites in various primary and immortalized human cells"><entity charOffset="17-27" id="DDI-PubMed.19500405.s2.e0" text="paclitaxel" /><entity charOffset="70-81" id="DDI-PubMed.19500405.s2.e1" text="gemcitabine" /><entity charOffset="166-177" id="DDI-PubMed.19500405.s2.e2" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.19500405.s2.e0" e2="DDI-PubMed.19500405.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19500405.s2.e0" e2="DDI-PubMed.19500405.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19500405.s2.e0" e2="DDI-PubMed.19500405.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19500405.s2.e1" e2="DDI-PubMed.19500405.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19500405.s2.e1" e2="DDI-PubMed.19500405.s2.e2" /></sentence><sentence text=" Therefore, we classified the drug-drug interaction and the effects of paclitaxel on deoxycytidine kinase (dCK) and cytidine deaminase (CDA) in three NSCLC cell lines"><entity charOffset="71-81" id="DDI-PubMed.19500405.s3.e0" text="paclitaxel" /><entity charOffset="85-98" id="DDI-PubMed.19500405.s3.e1" text="deoxycytidine" /><entity charOffset="116-124" id="DDI-PubMed.19500405.s3.e2" text="cytidine" /><pair ddi="false" e1="DDI-PubMed.19500405.s3.e0" e2="DDI-PubMed.19500405.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19500405.s3.e0" e2="DDI-PubMed.19500405.s3.e1" /><pair ddi="false" e1="DDI-PubMed.19500405.s3.e0" e2="DDI-PubMed.19500405.s3.e2" /><pair ddi="false" e1="DDI-PubMed.19500405.s3.e1" e2="DDI-PubMed.19500405.s3.e1" /><pair ddi="false" e1="DDI-PubMed.19500405.s3.e1" e2="DDI-PubMed.19500405.s3.e2" /></sentence><sentence text=" These enzymes are responsible for the metabolism of gemcitabine to its deaminated metabolite dFdU (80% of the parent drug) and the phosphorylated metabolites dFdCMP, dFdCDP and dFdCTP"><entity charOffset="53-64" id="DDI-PubMed.19500405.s4.e0" text="gemcitabine" /></sentence><sentence text=" These metabolites appear to relate to sensitivity and tolerability of gemcitabine based on previous animal and laboratory studies"><entity charOffset="71-82" id="DDI-PubMed.19500405.s5.e0" text="gemcitabine" /></sentence><sentence text="" /><sentence text="Three immortalized human cells representative of the most common histological subtypes identified in patients with advanced NSCLC were exposed to the individual drugs or combinations to complete a multiple drug effect analysis" /><sentence text=" These same cell lines were exposed to vehicle-control or paclitaxel and the mRNA levels, protein expression and specific activity of dCK and CDA were compared"><entity charOffset="58-68" id="DDI-PubMed.19500405.s8.e0" text="paclitaxel" /></sentence><sentence text=" Comparisons were made using a two-tailed paired t-test or analysis of variance with a P value of &lt; 0" /><sentence text="05 considered significant" /><sentence text="" /><sentence text="The multiple drug effect analysis indicated synergy for H460, H520 and H838 cells independent of sequence" /><sentence text=" As anticipated, paclitaxel-gemcitabine increased the number of G2/M cells, whereas gemcitabine-paclitaxel increased the number of G0/G1 or S cells"><entity charOffset="17-27" id="DDI-PubMed.19500405.s13.e0" text="paclitaxel" /><entity charOffset="28-39" id="DDI-PubMed.19500405.s13.e1" text="gemcitabine" /><entity charOffset="84-95" id="DDI-PubMed.19500405.s13.e2" text="gemcitabine" /><entity charOffset="96-106" id="DDI-PubMed.19500405.s13.e3" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.19500405.s13.e0" e2="DDI-PubMed.19500405.s13.e0" /><pair ddi="false" e1="DDI-PubMed.19500405.s13.e0" e2="DDI-PubMed.19500405.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19500405.s13.e0" e2="DDI-PubMed.19500405.s13.e2" /><pair ddi="false" e1="DDI-PubMed.19500405.s13.e0" e2="DDI-PubMed.19500405.s13.e3" /><pair ddi="false" e1="DDI-PubMed.19500405.s13.e1" e2="DDI-PubMed.19500405.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19500405.s13.e1" e2="DDI-PubMed.19500405.s13.e2" /><pair ddi="false" e1="DDI-PubMed.19500405.s13.e1" e2="DDI-PubMed.19500405.s13.e3" /><pair ddi="false" e1="DDI-PubMed.19500405.s13.e2" e2="DDI-PubMed.19500405.s13.e2" /><pair ddi="false" e1="DDI-PubMed.19500405.s13.e2" e2="DDI-PubMed.19500405.s13.e3" /></sentence><sentence text=" Paclitaxel significantly decreased dCK and CDA mRNA levels in H460 and H520 cells (40% to 60%, P &lt; 0"><entity charOffset="1-11" id="DDI-PubMed.19500405.s14.e0" text="Paclitaxel" /></sentence><sentence text="05) and lowered dCK protein (24% to 56%, P &lt; 0" /><sentence text="05) without affecting CDA protein" /><sentence text=" However, paclitaxel increased both dCK (10% to 50%) and CDA (75% to 153%) activity (P &lt; 0"><entity charOffset="10-20" id="DDI-PubMed.19500405.s17.e0" text="paclitaxel" /><entity charOffset="57-60" id="DDI-PubMed.19500405.s17.e1" text="CDA" /><pair ddi="false" e1="DDI-PubMed.19500405.s17.e0" e2="DDI-PubMed.19500405.s17.e0" /><pair ddi="false" e1="DDI-PubMed.19500405.s17.e0" e2="DDI-PubMed.19500405.s17.e1" /></sentence><sentence text="05)" /><sentence text=" Paclitaxel caused substantial declines in the accumulation of the deaminated and phosphorylated metabolites in H520 cells (P &lt; 0"><entity charOffset="1-11" id="DDI-PubMed.19500405.s19.e0" text="Paclitaxel" /></sentence><sentence text="05); the metabolites were not measurable in the remaining two cell lines" /><sentence text=" The ratio of dCK to CDA mRNA levels corresponded to the combination index (CI) estimated for sequential paclitaxel-gemcitabine"><entity charOffset="105-115" id="DDI-PubMed.19500405.s21.e0" text="paclitaxel" /><entity charOffset="116-127" id="DDI-PubMed.19500405.s21.e1" text="gemcitabine" /><entity charOffset="21-31" id="DDI-PubMed.19500405.s21.e2" text="CDA" /><pair ddi="false" e1="DDI-PubMed.19500405.s21.e2" e2="DDI-PubMed.19500405.s21.e2" /><pair ddi="false" e1="DDI-PubMed.19500405.s21.e2" e2="DDI-PubMed.19500405.s21.e0" /><pair ddi="false" e1="DDI-PubMed.19500405.s21.e2" e2="DDI-PubMed.19500405.s21.e1" /><pair ddi="false" e1="DDI-PubMed.19500405.s21.e0" e2="DDI-PubMed.19500405.s21.e0" /><pair ddi="false" e1="DDI-PubMed.19500405.s21.e0" e2="DDI-PubMed.19500405.s21.e1" /></sentence><sentence text="" /><sentence text="In summary, paclitaxel altered the mRNA levels and specific activity of dCK and CDA and these effects could be dependent on histological subtype"><entity charOffset="12-22" id="DDI-PubMed.19500405.s23.e0" text="paclitaxel" /><entity charOffset="80-89" id="DDI-PubMed.19500405.s23.e1" text="CDA" /><pair ddi="false" e1="DDI-PubMed.19500405.s23.e0" e2="DDI-PubMed.19500405.s23.e0" /><pair ddi="false" e1="DDI-PubMed.19500405.s23.e0" e2="DDI-PubMed.19500405.s23.e1" /></sentence><sentence text=" More cell and animal studies are needed to further characterize the relationship between mRNA levels and the overall drug-drug interaction and the potential to use histological subtype as a predictive factor in the selection of an appropriate anticancer drug regimen" /><sentence text="" /></document>